Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in January 2009, to inform of new safety information and advice.
|
Date issued
|
Product
|
Safety information
|
|---|---|---|
| 16 January 2009 | Efavirenz: SUSTIVA and STOCRIN (339Kb) |
SUSTIVA efavirenz 100 mg hard capsule formulation will be discontinued. The following SUSTIVA formulations remain available: 50 mg and 200 mg hard capsules; 600 mg film-coated tablets; 30 mg/mL oral solution In addition, STOCRIN efavirenz 200 mg film-coated tablets may be available on request from January 2009 for individual patients who meet specific criteria |
| Week commencing 5 January 2009 | Temsirolimus: Torisel (66Kb) |
Hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions) have been associated with the administration of temsirolimus (Torisel) See also Drug Safety Update January 2009, p3 |
